

## Curriculum Vitae

**Gabriella Egeo**  
(*Ai sensi dell'art 46 del DPR 445/2000*)

### Formazione

- Maturità scientifica conseguita presso il Liceo scientifico Luigi Costanzo in Decollatura (CZ) con votazione 54/60.
- Laureata in Medicina e Chirurgia in data 18.11.2000 presso l'Università di Roma "La Sapienza" con tesi in Neurologia dal titolo "Nuova generazione di farmaci antiepilettici: vantaggi e svantaggi" con votazione 110/110 e lode.
- Abilitata presso l'Università di Roma "La Sapienza" nella prima sessione del 2001.
- Iscritta all'Ordine dei Medici nella regione Calabria dal 18.07.2001
- Specializzazione in Neurologia in data 08.11.2006 presso l'Università di Roma "La Sapienza" con tesi dal titolo "Epilessia parziale temporale laterale con sintomi uditivi: aspetti elettroclinici e genetici" con votazione 70/70 (D. lgs. 257/91)
- Dottorato di Ricerca in Neuroscienze all'Università di Roma "La Sapienza" conseguito in data 27.03.2010 presso l'Università di Roma "La Sapienza" con tesi in Neurologia dal titolo "Epilessia temporale laterale familiare (con e senza mutazione LGI1): caratteristiche elettrocliniche ed analisi genetica"

### Altro

- Nel 2004 (aprile-agosto) ha prestato servizio presso il Centro di Salute di Bafia (Camerun) partecipando ad un progetto di ricerca Minga Onlus/Policlinico Umberto I° riguardante la prevalenza dell'epilessia nella regione centrale del Camerun.
- Corso base in Elettroencefalografia Clinica. Gargnano (BS), Palazzo Feltrinelli marzo 2005.
- Scuola di Formazione sulle Cefalee. Corso di Perfezionamento in diagnosi e terapia delle cefalee in 3 Moduli della durata di un anno (IX Corso ASC). Conseguito a febbraio 2011.

### Attività lavorativa

Dal 1999 ha frequentato reparto, D.H, ambulatorio ed il Centro per la Cura dell'Epilessia della Neurologia B del Dipartimento di Scienze Neurologiche del Policlinico Umberto I°. Presso tale centro, ha svolto attività clinica (di reparto e ambulatoriale) e di ricerca. Ha partecipato attivamente inoltre all'attività del laboratorio di Elettroencefalografia (EEG) diretto dalla Dott.ssa Giallonardo, perfezionando le sue conoscenze sia in riferimento alla Video-EEG che alla registrazione EEG prolungata delle 24 ore.

Ha svolto e continua a svolgere attività di ricerca in ambito neurologico, neurofisiologico e neurofarmacologico delle epilessie interessandosi in particolare degli studi epidemiologici e genetici.

Ha appreso ed applica correttamente la tecnica di refertazione EEG.

Ha partecipato a numerose sperimentazioni farmacologici per gli studi sull'epilessia e sull'emicrania (vedi sperimentazioni cliniche effettuate)

Nel 2006 ha lavorato presso l'IRCCS San Raffaele Pisana prima come Neurologo di reparto, dal 2012 al 2020 come Neurologo presso ex-art 26 e svolgendo attività ambulatoriale con particolare interesse per le Cefalee.

Dal 2009 ha un contratto di ricerca con l'IRCCS San Raffaele Roma dove svolge attività di ricerca e trials clinici nell'ambito delle cefalee (vedi sperimentazioni cliniche effettuate).

Dal gennaio 2009 al giugno 2020 ha lavorato in qualità di consulente Neurologo presso l'Istituto di Medicina e Scienza dello Sport (CONI).

Dal 2010 lavora come neurologo per il SSN presso ASL del territorio di Roma.

### **Contributi a Congressi Nazionali e Internazionali**

- Studio video-EEG dello Stato di Male epilettico: correlazioni elettro-cliniche, diagnosi eziologica, considerazioni terapeutiche e out-come. F Mari, J Fattouch, C Di Bonaventura, **G Egeo**, AE Vaudano, AT Giallonardo, M Manfredi; Congresso Nazionale LICE 2004, Milano.
- Efficacia del Levetiracetam nel trattamento delle epilessie generalizzate idiopatiche. J Fattouch, C Di Bonaventura, F Mari, A Mascia, **G Egeo**, AE Vaudano, M Prencipe, AT Giallonardo, M Manfredi. Congresso Nazionale LICE 2004, Milano.
- SdM elettrico non evidente all'EEG di superficie come possibile fattore causale dell'atrofia progressiva nell'encefalite di Rasmussen ad esordio tardivo. J Fattouch, C, Di Bonaventura, G Di Gennaro, **G Egeo**, V Esposito, F Giangaspero, F Mari, A Mascia, PP Quarato, AE Vaudano, M Manfredi, AT Giallonardo. Congresso Nazionale LICE 2004, Milano.
- Assenze tipiche versus Pseudoassenze: utilità dello studio EEG/fMRI nella definizione sindromica. Anna E. Vaudano, Carlo Di Bonaventura, Marco Carni, J Fattouch, F Mari, **G Egeo**, Patrizia Pantano, Walter Nucciarelli, Gino Gareffa, Bruno Maraviglia, Luigi Bozzao, Mario Manfredi, Anna T. Giallonardo. Congresso Nazionale LICE 2004, Milano.
- Studio EEG/fMRI delle attività critiche elettro-cliniche. Carlo Di Bonaventura, Marco Carni, Anna E. Vaudano, J Fattouch, F Mari, **G Egeo**, Patrizia Pantano, Walter Nucciarelli, Gino Gareffa, Bruno Maraviglia, Luigi Bozzao, Mario Manfredi, Anna T. Giallonardo. Congresso Nazionale LICE 2004, Milano.
- Efficacia e tollerabilità del Levetiracetam nel trattamento di epilessia associata ad epatopatie. **G Egeo**, C Di Bonaventura, J Fattouch, A Vaudano, F Mari, A Zarabla, M Prencipe, M Manfredi e AT Giallonardo. LICE 2005.
- Experience with levetiracetam in primary generalized epilepsy. Mari F, **Egeo G**, Di Bonaventura C, Manfredi M, Fattouch J, Vaudano AE, Prencipe M, Giallonardo AT. *European Journal of Neurology*, 12 (S2): 345. Cernobio 2005
- Modificazioni emodinamiche del talamo in corso di attività critiche: differenti pattern fMRI in pazienti con crisi parziali e generalizzate. Anna E. Vaudano, Carlo Di Bonaventura, Marco Carni, J Fattouch, F Mari, **G Egeo**, F Bonini, Patrizia Pantano, Walter Nucciarelli, Gino Gareffa, Bruno Maraviglia, Luigi Bozzao, Mario Manfredi, Anna T. Giallonardo. Congresso Nazionale LICE 2006, Pisa.
- Caratteristiche elettro-cliniche di epilessia parziale associata ad anomalia complessa del cromosoma 18 (monosomia 18p11.2pter e trisomia 18q23qter): descrizione di un caso clinico. **G Egeo**, C Di Bonaventura, J Fattouch, A Vaudano, F Mari, F Bonini, M Prencipe, M Manfredi e AT Giallonardo. Pisa 2006
- Impiego della risonanza magnetica funzionale (fMRI) nello studio dell'epilessia: studio EEG/fMRI delle crisi di assenza nello spettro delle differenti sindromi epilettiche. AE Vaudano, C Di Bonaventura, J Fattouch, F Mari, **G Egeo**, F Bonini, P Pantano, L Bozzao, AT Giallonardo, G Garreffa, M Carni, B Maraviglia, M Manfredi. LICE 2007, Reggio Calabria.
- Epilessia parziale temporale laterale familiare con e senza mutazione LGII: pattern elettro-clinici critici nei pazienti farmacoresistenti. **G. Egeo**, C. Di Bonaventura, J. Fattouch, F. Mari, A.E. Vaudano, C. Nobile, A. Pizzuti, M. Prencipe, M. Manfredi, A.T. Giallonardo Reggio Calabria, LICE 2007.
- Pattern elettro-clinici della "vertigine" epilettica isolata. J. Fattouch, C. Di Bonaventura, F. Mari, **G. Egeo**, A.E. Vaudano, F. Bonini, S. Petrucci, G. Ricciardo Rizzo, M. Manfredi, M. Prencipe, A.T. Giallonardo. Reggio Calabria, LICE 2007.
- Studio di risonanza magnetica con tecnica DWI in pazienti con stato di male parziale. F. Bonini, J. Fattouch, C. Di Bonaventura, F. Mari, **G. Egeo**, A.E. Vaudano, S. Petrucci, G. Ricciardo Rizzo, M. Manfredi, M. Prencipe, A.T. Giallonardo. Reggio Calabria, LICE 2007.

- Stato di Male ricorrente in pazienti con epilessia: caratteristiche elettrocliniche e inquadramento sindromico. F. Mari, C. Di Bonaventura, J. Fattouch, **G. Egeo**, A.E. Vaudano, F. Bonini, S. Petrucci, G. Ricciardo Rizzo, M. Manfredi, A. Berardelli, M. Prencipe, A.T. Giallonardo. Reggio Calabria, LICE 2007.
- Impiego della risonanza magnetica funzionale (fMRI) nello studio delle crisi parziali: definizione del correlato emodinamico e del network sotteso alle attività critiche S. Petrucci, J. Fattouch, C. Di Bonaventura, M. Carni, A.E. Vaudano, **G. Egeo**, S.L. Lapenta, P. Pantano, B. Maraviglia, M. Prencipe, L. Bozzao, M. Manfredi, A.T. Giallonardo (Roma), Venezia, LICE 2008.
- ADTLE con crisi farmacoresistenti e stato di male parziale ricorrente a semiologia disfasica in una famiglia con nuova mutazione LGI1: caratteristiche elettro-cliniche, genetiche ed EEG/fMRI. C. Di Bonaventura, M. Carni, J. Fattouch, A.E. Vaudano, E. Diani, **G. Egeo**, F. Bonini, S. Petrucci, P. Pantano, B. Maraviglia, M. Prencipe, L. Bozzao, M. Manfredi, A.T. Giallonardo, C. Nobile (Roma, Padova), Venezia, LICE 2008.
- Studio neurofisiologico e di neuroimaging funzionale in una paziente con eterotopia a banda sottocorticale (da mutazione del gene DCX), fenomeno FOS e crisi riflesse alla lettura. F. Bonini, J. Fattouch, C. Di Bonaventura, S. Pontecorvo, **G. Egeo**, A.E. Vaudano, S. Petrucci, G. Ricciardo Rizzo, L. Lapenta, E. Tinelli, M. Carni, B. Maraviglia, M. Manfredi, M. Prencipe, A. Francia, A.T. Giallonardo (Roma, Pozzilli - IS), Venezia, LICE 2008.
- Dalla Risonanza Magnetica Funzionale (fMRI) al network epilettogeno: studio di "effective connectivity" durante crisi parziali complesse. A.E. Vaudano, Simona Petrucci, C. Di Bonaventura, M. Carni, L. Lapenta, J. Fattouch, **G. Egeo**, V. Nucciarelli, L. Lemieux, A.T. Giallonardo. LICE 2009, Sorrento.
- Crisi focale indotta da transitoria ipoglicemia in paziente affetta da diabete insulinodipendente. L. Lapenta, C. Di Bonaventura, J. Fattouch, S. Petrucci, **G. Egeo**, A.E. Vaudano, F. Bonini, S. Casciato, S. Gagliardi, M. Manfredi, A.T. Giallonardo. LICE 2009 Sorrento.
- Modificazioni emodinamiche ictali correlate alla vertigine epilettica. S. Petrucci, L. Lapenta, F. Bonini, S. Casciato, S. Gagliardi, J. Fattouch, C. Di Bonaventura, **G. Egeo**, A.E. Vaudano, M. Manfredi, M. Prencipe, A.T. Giallonardo, LICE 2009 Sorrento.
- "Subtle" Kojevnikow syndrome ad esordio tardivo: studio EEG/fMRI. A.E. Vaudano, C. Di Bonaventura, M. Carni, L. Lapenta, Casciato S, J. Fattouch, **G. Egeo**, V. Nucciarelli, L. Lemieux, A.T. Giallonardo. Policentrico 2010, Roma.
- Epilessia parziale temporale laterale familiare con e senza mutazione LGI1: pattern elettro-clinici critici nei pazienti farmaco resistenti. **G. Egeo**, C. Di Bonaventura, J. Fattouch, A.E. Vaudano, F. Mari, F. Bonini, M. Prencipe, C. Nobile, A. Pizzuti, M. Manfredi e A.T. Giallonardo. LICE 2010
- Epilessia parziale benigna a punte centro-temporali: studio multimodale delle attività patologiche. A.E. Vaudano, C. Di Bonaventura, M. Carni, J. Fattouch, **G. Egeo**, L. Lapenta, S. Casciato, V. Nucciarelli, P. Pantano, M. Prencipe, M. Manfredi, L. Lemieux, A.T. Giallonardo. LICE 2010, Mantova.
- Multimodal approach in patients with BECTS: EEG source reconstruction and EEG/fMRI study of the pathological activity. A.E. Vaudano, C. Di Bonaventura, M. Carni, J. Fattouch, **G. Egeo**, L. Lapenta, S. Casciato, V. Nucciarelli, P. Pantano, M. Prencipe, M. Manfredi, L. Lemieux, A.T. Giallonardo. SIN 2010, Catania; Congresso Nazionale Neuroradiologia Funzionale 2011, Milano.
- Studio EEG/fMRI durante stato di male di punta e polipunta-onda in un paziente affetto da Epilessia Mioclonica Giovanile. A.E. Vaudano, C. Di Bonaventura, M. Carni, J. Fattouch, **G. Egeo**, L. Lapenta, S. Casciato, V. Nucciarelli, P. Pantano, M. Prencipe, M. Manfredi, L. Lemieux, A.T. Giallonardo. Policentrico 2011, Roma
- A case-control study on excessive daytime sleepiness in chronic migraine. C. Aurilia, N. Vanacore, **G. Egeo**, L. Fofi, P. Barbanti. Stresa, 7th International Headache Seminary. Focus on Headaches: Update and upcoming developments. 26-29 May, 2011.
- Establishment of a biorepository for migraine research: the experience of interinstitutional Multidisciplinary BioBank (BioBIM). F. Guadagni, R. Palmirotta, G. Ludovici, M. L. De Marchis, A. Savonarola, B. Leone, A. Spila, P. Somma, **G. Egeo**, C. Aurilia, L. Fofi, P. Barbanti. Stresa, 7th International Headache Seminary. Focus on Headaches: Update and upcoming developments. 26-29 May, 2011.
- The Interinstitutional Multidisciplinary BioBank (BioBIM): The establishment of a biorepository for migraine research. F. Guadagni, R. Palmirotta, G. Ludovici, M.L. De Marchis, A. Savonarola, B. Leone, A. Spila, F. De Angelis, **G. Egeo**, C. Aurilia, L. Fofi, P. Barbanti. Berlino. 15th Congress of the International Headache Society. 23-26 Giugno 2011.

- Headache frequency and characteristics in chronic cocaine users: a cross sectional study. Luisa Fofi, Valerio Orlandi, Nicola Vanacore, Maria Cristina Mizzone, Alba Rosa, Cinzia Aurilia, **Gabriella Egeo**, Pietro Casella, P. Barbanti. Berlino. 15th Congress of the International Headache Society. 23-26 Giugno 2011.
- Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a doubleblind trial. Piero Barbanti, Luisa Fofi, Valentina Dall'Armi, Cinzia Aurilia, **Gabriella Egeo**, Nicola Vanacore, Stefano Bonassi. Berlino. 15th Congress of the International Headache Society. 23-26 Giugno 2011.
- Look beyond comt genotype for catecholamines derangement in migraine: the biobim rs4818 and rs4680 polymorphisms study. P. Barbanti, M.L. De Marchis, R. Palmirota, **G. Egeo**, C. Aurilia, L. Fofi, S. Piroso, C. Ialongo, G. D'Andrea, F. Guadagni. 56<sup>th</sup> Annual Scientific Meeting of the American Headache Society. 26-29 Giugno 2015.
- Association Between Migraine and SOD1 and SOD2 genes polymorphisms: *The BioBIM Study*. Piero Barbanti, Raffaele Palmirota, Maria Laura De Marchis, Giorgia Ludovici, Cristiano Ialongo, **Gabriella Egeo**, Cinzia Aurilia, Luisa Fofi, Patrizia Ferroni, David Della-Morte and Fiorella Guadagni. 17th Congress of the International Headache Society. 14-17 Maggio 2015 Valencia.
- Noninvasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study. P. Barbanti, L. Grazi, **G. Egeo**, A.M. Padovan, E. Liebler, G. Bussone. 17th Congress of the International Headache Society. 14-17 Maggio 2015 Valencia.
- Corso teorico-pratico di aggiornamento su diagnosi e gestione dell'Emicrania. "Emicrania al Centro", Roma 20 novembre 2010-IRCCS San Raffaele Pisana. **Relatrice**.
- Corso di Formazione ECM "La gestione delle cefalee nello studio del medico di medicina generale: dalla diagnosi alla terapia", Roma il 2 ottobre 2015 IRCCS San Raffaele Pisana. **Relatrice**.
- Seminario di Formazione Avanzata sulle Cefalee. ASC. Roma 23-25 Novembre 2018. **Relatrice**.
- Attività di docenza nell'ambito dei Corsi per Operatori Socio-Sanitari per l'Azienda di Servizi alla Persona Disabile Visiva S. Alessio - Margherita di Savoia dal 2021 al 2023.

## Publicazioni

- 1) Pizzuti A, Flex E, Di Bonaventura C, Dottorini T, **Egeo G**, Manfredi M, Dallapiccola B. Epilepsy with auditory features: a LGI1 gene mutation suggests a loss of function mechanism. *Ann Neurol*.2003Mar;53(3):396-9.
- 2) Di Bonaventura C, Fattouch J, Mari F, **Egeo G**, Vaudano AE, Prencipe M, Manfredi M, Giallonardo AT. Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. *Epileptic Disord*. 2005 Sep;7(3):231.
- 3) Flex E, Pizzuti A, Di Bonaventura C, Douzgou S, **Egeo G**, Fattouch J, Manfredi M, Dallapiccola B, Giallonardo AT. LGI1 gene mutation screening in sporadic partial epilepsy with auditory features. *J Neurol*. 2005 Jan;252(1):62-6.
- 4) Di Bonaventura C, Mari F, Fattouch J, **Egeo G**, Vaudano AE, Manfredi M, Prencipe M, Giallonardo AT. Use of levetiracetam in treating epilepsy associated with other medical conditions. *Acta Neurol Scand*. 2006 Feb;113(2):82-6
- 5) Mari F, Di Bonaventura C, Vanacore N, Fattouch J, Vaudano AE, **Egeo G**, Berardelli A, Manfredi M, Prencipe M, Giallonardo AT. Video-EEG study of psychogenic nonepileptic seizures: differential characteristics in patients with and without epilepsy. *Epilepsia*. 2006;47 Suppl 5:64-7.
- 6) Striano P, Gambardella A, Coppola A, Di Bonaventura C, Bovo G, Diani E, Boaretto F, Egeo G, Ciampa C, Labate A, Testoni S, Passarelli D, Manna I, Sferro C, Aguglia U, Caranci F, Giallonardo AT, Striano S, Nobile C, Michelucci R. Familial mesial temporal lobe epilepsy (FMTLE) : a clinical and genetic study of 15 Italian families. *J Neurol*. 2008 Jan;255(1):16-23.
- 7) Prischich F, De Rinaldis M, Bruno F, **Egeo G**, Santori C, Zappaterreno A, Fattouch J, Di Bonaventura C, Bada J, Russo G, Pizzuti A, Cardona F, Sa'a, Vullo V, Giallonardo AT, D'Erasmo E, Pelliccia A, Vanacore N. High prevalence of epilepsy in a village in the Littoral Province of Cameroon. *Epilepsy Res*. 2008 Dec;82(2-3):200-10.
- 8) Diani E, Di Bonaventura C, Mecarelli O, Gambardella A, Elia M, Bovo G, Bisulli F, Pinardi F, Binelli S, **Egeo G**, Castellotti B, Striano P, Striano S, Bianchi A, Ferlazzo E, Vianello V, Coppola G, Aguglia U, Tinuper P, Giallonardo AT, Michelucci R, Nobile C. Autosomal dominant lateral temporal epilepsy: absence of mutations in ADAM22 and Kv1 channel genes encoding LGI1-associated proteins. *Epilepsy Res*. 2008 Jul;80(1):1-8.
- 9) Bovo G, Diani E, Bisulli F, Di Bonaventura C, Striano P, Gambardella A, Ferlazzo E, **Egeo G**, Mecarelli O, Elia M, Bianchi A, Bortoluzzi S, Vettori A, Aguglia U, Binelli S, De Falco A, Coppola G, Gobbi G, Sofia V, Striano S, Tinuper P, Giallonardo AT, Michelucci R, Nobile C. Analysis of LGI1 promoter sequence, PDYN and GABBR1 polymorphisms in sporadic and familial lateral temporal lobe epilepsy. *Neurosci Lett*. 2008 May 2;436(1):23-6.
- 10) Di Bonaventura C, Carni M, Diani E, Fattouch J, Vaudano EA, **Egeo G**, Pantano P, Maraviglia B, Bozzao L, Manfredi M, Prencipe M, Giallonardo TA, Nobile C. Drug resistant ADLTE and recurrent partial status epilepticus

- with dysphasic features in a family with a novel LGI1 mutation: electroclinical, genetic, and EEG/fMRI findings. *Epilepsia*. 2009 Nov; 50(11):2481-6.
- 11) Busolin G, Malacrida S, Bisulli F, Striano P, Di Bonaventura C, **Egeo G**, Pasini E, Cianci V, Ferlazzo E, Bianchi A, Coppola G, Elia M, Mecarelli O, Gobbi G, Casellato S, Marchini M, Binelli S, Freri E, Granata T, Posar A, Parmeggiani A, Vigliano P, Boniver C, Aguglia U, Striano S, Tinuper P, Giallonardo AT, Michelucci R, Nobile C. Association of intronic variants of the KCNAB1 gene with lateral temporal epilepsy. *Epilepsy Res*. 2011 Mar;94(1-2):110-6.
  - 12) Barbanti P, Aurilia C, **Egeo G**, Fofi L. Hypertension as a risk factor for migraine chronification. *Neurol Sci*. 2011 May;32 Suppl 1:S111-5.
  - 13) Barbanti P, Aurilia C, **Egeo G**, Fofi L. Migraine prophylaxis: what is new and what we need? *Neurol Sci*. 2011 May;32 Suppl 1:S111-5.
  - 14) Di Bonaventura C, Operto FF, Busolin G, **Egeo G**, D'Aniello A, Vitello L, Smaniotto G, Furlan S, Diani E, Michelucci R, Giallonardo AT, Coppola G, Nobile C. Low penetrance and effect on protein secretion of LGI1 mutations causing autosomal dominant lateral temporal epilepsy. *Epilepsia*. 2011 Jul;52(7):1258-64.
  - 15) Rigon L, Vettori A, Busolin G, **Egeo G**, Pulitano P, Santulli L, Pasini E, Striano P, la Neve A, Vianello Dri V, Boniver C, Gambardella A, Banfi P, Binelli S, Di Bonaventura C, Striano S, de Falco F, Giallonardo AT, Mecarelli O, Michelucci R, Nobile C. ADAM23, a Gene Related to LGI1, Is Not Linked to Autosomal Dominant Lateral Temporal Epilepsy. *Epilepsy Res Treat*. 2011;2011:258365.
  - 16) Vaudano AE, Di Bonaventura C, Carni M, Rodionov R, Lapenta L, Casciato S, Fattouch J, **Egeo G**, Pantano P, Nucciarelli V, Maraviglia B, Prencipe M, Lemieux L, Giallonardo AT. Ictal haemodynamic changes in a patient affected by "subtle" Epilepsia Partialis Continua. *Seizure*. 2012 Jan;21(1):65-9.
  - 17) Fanella M, Fattouch J, Casciato S, Lapenta L, Morano A, **Egeo G**, Manfredi M, Prencipe M, Giallonardo AT, Di Bonaventura C. Ictal epileptic headache as "subtle" symptom in generalized idiopathic epilepsy. *Epilepsia*. 2012 Feb; 53 (7):67-70.
  - 18) EPICURE Consortium, Leu C, de Kovel CG, Zara F, Striano P, Pezzella M, Robbiano A, Bianchi A, Bisulli F, Coppola A, Giallonardo AT, Beccaria F, Trenité DK, Lindhout D, Gaus V, Schmitz B, Janz D, Weber YG, Becker F, Lerche H, Kleefuss-Lie AA, Hallman K, Kunz WS, Elger CE, Muhle H, Stephani U, Møller RS, Hjalgrim H, Mullen S, Scheffer IE, Berkovic SF, Everett KV, Gardiner MR, Marini C, Guerrini R, Lehesjoki AE, Siren A, Nabbout R, Baulac S, Leguern E, Serratosa JM, Rosenow F, Feucht M, Unterberger I, Covanis A, Suls A, Weckhuysen S, Kaneva R, Caglayan H, Turkdogan D, Baykan B, Bebek N, Ozbek U, Hempelmann A, Schulz H, Rüschenhoff F, Trucks H, Nürnberg P, Avanzini G, Koeleman BP, Sander T. Genome-wide linkage meta-analysis identifies susceptibility loci at 2q34 and 13q31.3 for genetic generalized epilepsies". *Epilepsia*. 2012 Feb;53(2):308-18. \***Egeo G** (collaborator) PMID: 22242659
  - 19) Barbanti P, Aurilia C, **Egeo G**, Fofi L. Future trends in drugs for migraine prophylaxis. *Neurol Sci*. 2012 May;33 Suppl 1:S137-40. Review.
  - 20) Fofi L, Giugni E, Vadalà R, Vanacore N, Aurilia C, **Egeo G**, Pierallini A, Barbanti P. Cerebral transverse sinus morphology as detected by MR venography in patients with chronic migraine. *Headache* 2012 Sep;52(8):1254-61.
  - 21) Barbanti P, Fofi L, Dall'Armi V, Aurilia C, **Egeo G**, Vanacore N, Bonassi S. Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial. *J Headache Pain*. 2012 Jul;13(5):407-14.
  - 22) Barbanti P, Aurilia C, **Egeo G**, Fofi L, Vanacore N. A case-control study on excessive daytime sleepiness in chronic migraine. *Sleep Med*. 2013 Mar;14 (3):278-81.
  - 23) Palmirotta R, Barbanti P, Ludovici G, **Egeo G**, Aurilia C, Fofi L, De Marchis ML, Spila A, Ferroni P, Della-Morte D, Guadagni F. Establishment of a biorepository for migraine research: the experience of Interinstitutional Multidisciplinary BioBank (BioBIM). *Neurol Sci*. 2013 Sep;34(9):1659-63.
  - 24) Palmirotta R, Ludovici G, **Egeo G**, Ialongo C, Aurilia C, Fofi L, De Marchis ML, Della-Morte D, Barbanti P, Guadagni F. Prion protein gene M129V polymorphism and variability in age at migraine onset. *Headache*. 2013 Mar;53(3):540-5.
  - 25) Michelucci R, Pasini E, Malacrida S, Striano P, Bonaventura CD, Pulitano P, Bisulli F, **Egeo G**, Santulli L, Sofia V, Gambardella A, Elia M, de Falco A, Neve A, Banfi P, Coppola G, Avoni P, Binelli S, Boniver C, Pisano T, Marchini M, Dazzo E, Fanciulli M, Bartolini Y, Riguzzi P, Volpi L, de Falco FA, Giallonardo AT, Mecarelli O, Striano S, Tinuper P, Nobile C. Low penetrance of autosomal dominant lateral temporal epilepsy in Italian families without LGI1 mutations. *Epilepsia*. 2013 Jul;54(7):1288-97.
  - 26) Barbanti P, Fofi L, Aurilia C, **Egeo G**. Dopaminergic symptoms in migraine. *Neurol Sci*. 2013 May;34 Suppl 1:S67-70.
  - 27) Fanella M, **Egeo G**, Fattouch J, Casciato S, Lapenta L, Morano A, Giallonardo AT, Di Bonaventura C. Oxcarbazepine-induced myoclonic status epilepticus in juvenile myoclonic epilepsy. *Epileptic Disord*. 2013 Jun;15(2):181-7.

- 28) Bonini F, **Egeo G**, Fattouch J, Fanella M, Morano A, Giallonardo AT, di Bonaventura C. Natural evolution from idiopathic photosensitive occipital lobe epilepsy to idiopathic generalized epilepsy in an untreated young patient. *Brain Dev.* 2014 Apr;36(4):346-50.
  - 29) Fanciulli M, Di Bonaventura C, **Egeo G**, Fattouch J, Dazzo E, Radovic S, Spadotto A, Giallonardo AT, Nobile C. Suggestive linkage of familial mesial temporal lobe epilepsy to chromosome 3q26. *Epilepsy Res.* 2014 Feb;108(2):232-40.
  - 30) Palmirotta R, Barbanti P, Ludovici G, De Marchis ML, Ialongo C, **Egeo G**, Aurilia C, Fofi L, Abete P, Spila A, Ferroni P, Della-Morte D, Guadagni F. Association between migraine and ACE gene (insertion/deletion) polymorphism: the BioBIM study. *Pharmacogenomics.* 2014 Feb;15(2):147-55.
  - 31) Fofi L, Orlandi V, Vanacore N, Mizzoni MC, Rosa A, Aurilia C, **Egeo G**, Casella P, Barbanti P. Headache in chronic cocaine users: A cross-sectional study. *Cephalalgia.* 2014 Feb 5;34(9):671-678.
  - 32) Barbanti P, **Egeo G**, Aurilia C, Fofi L, Della-Morte D. Drugs targeting nitric oxide synthase for migraine treatment. *Expert Opin Investig Drugs.* 2014 Aug;23(8):1141-8. Barbanti P, Egeo G, Aurilia C, Fofi L. Treatment of tension-type headache: from old myths to modern concepts. *Neurol Sci.* 2014 May;35 Suppl 1:17-21.
  - 33) Palmirotta R, Barbanti P, De Marchis ML, **Egeo G**, Aurilia C, Fofi L, Ialongo C, Valente MG, Ferroni P, Della-Morte D, Guadagni F. Is SOD2 Ala16Val polymorphism associated with migraine with aura phenotype? *Antioxid Redox Signal.* 2015 Jan 20;22(3):275-9
  - 34) Palmirotta R, Barbanti P, Ialongo C, De Marchis ML, Alessandrini J, **Egeo G**, Aurilia C, Fofi L, Valente MG, Ferroni P, Della-Morte D, Guadagni F. Progesterone receptor gene (PROGINS) polymorphism correlates with late onset of migraine. *DNA Cell Biol.* 2015 Mar;34(3):208-12
  - 35) Barbanti P, Egeo G. Pharmacological trials in migraine: it's time to reappraise where the headache is and what the pain is like. *Headache.* 2015 Mar;55(3):439-41.
  - 36) De Marchis ML, Barbanti P, Palmirotta R, **Egeo G**, Aurilia C, Fofi L, Piroso S, Ialongo C, Della-Morte D, D'Andrea G, Ferroni P, Guadagni F. Look beyond CatecholO-Methyltransferase genotype for catecholamines derangement in migraine: the BioBIM rs4818 and rs4680 polymorphisms study. *J Headache Pain.* 2015 Dec;16:520.
  - 37) Barbanti P, **Egeo G**, Fofi L, Aurilia C, Piroso S. Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine. *Neurol Sci.* 2015 May;36 Suppl 1:29-32.
  - 38) Barbanti P, Grazi L, **Egeo G**, Padovan AM, Liebler E, Bussone G. Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study. *J Headache Pain.* 2015 Dec;16:61. Epub 2015 Jun 30.
  - 39) Ferroni P, Barbanti P, Spila A, Fratangeli F, Aurilia C, Fofi L, **Egeo G**, Guadagni F. Circulating Biomarkers In Migraine. New Opportunities For Precision Medicine. *Curr Med Chem.* 2018 Jun 22.
  - 40) Ferroni P, Barbanti P, Aurilia C, **Egeo G**, Fofi L, La Farina F, Valente MG, De Marchis ML, Spila A, Palmirotta R, Della-Morte D, Guadagni F. Procoagulant imbalance in premenopausal women with chronic migraine. *Neurology.* 2017 Oct 3;89(14):1525-1527.
  - 41) Grazi L, **Egeo G**, Liebler E, Padovan AM, Barbanti P. Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients: a preliminary safety study. *Neurol Sci.* 2017 May;38(Suppl 1):197-199.
  - 42) Barbanti P, Aurilia C, Fofi L, **Egeo G**, Ferroni P. The role of anti-CGRP antibodies in the pathophysiology of primary headaches. *Neurol Sci.* 2017 May;38(Suppl 1):31-35.
  - 43) Barbanti P, Fofi L, Aurilia C, **Egeo G**, Caprio M. Ketogenic diet in migraine: rationale, findings and perspectives. *Neurol Sci.* 2017 May;38(Suppl 1):111-115.
  - 44) Barbanti P, Aurilia C, **Egeo G**, Fofi L, Piroso S. Chronic migraine: treatability, refractoriness, pseudo-refractoriness. *J Headache Pain.* 2015 Dec;16(Suppl 1):A39.
  - 45) Vanacore N, Cevoli S, Torelli P, Aurilia C, **Egeo G**, Fofi L, Grazi L, Bussone G, Manzoni GC, Cortelli P, Barbanti P. A proposal for a national registry on chronic migraines. *J Headache Pain.* 2015 Dec;16(Suppl 1):A40.
  - 46) Grazi L, **Egeo G**, Calhoun AH, McClure CK, Liebler E, Barbanti P. Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study. *J Headache Pain.* 2016 Dec;17(1):91. Epub 2016 Oct 3.
  - 47) Barbanti P, **Egeo G**. Pharmacological trials in migraine: it's time to reappraise where the headache is and what the pain is like. *Headache.* 2015 Mar;55(3):439-41. Epub 2014 Dec 19.
  - 48) Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, Luisa Fofi. Erenumab: from scientific evidence to clinical practice—the first Italian real-life data. *Neurological Science.* In press.
- Capitolo sul libro *Le Cefalee: “Cefalea di tipo tensivo: cenni di fisiopatologia e terapia”*. Piero Barbanti, **Gabriella Egeo**. 2015. Pg 113-123.
  - Capitolo sul libro *“Mangia sano che ti passa”*. Piero Barbanti, **Gabriella Egeo**. 2017.

**Altro:**

Protocolli di sperimentazioni cliniche a fini diagnostici e terapeutici effettuati come Subinvestigator o Study Coordinator:

1. GlaxoSmithKline: AVA 102672

“A 54-week, double-blind, randomised, placebo- controlled, parallel- group study to investigate the effects of rosiglitazone (extended-release tablets) as adjunctive therapy to donepezil on cognition and overall clinical response in APOE ε4-stratified subjects with mild to moderate Alzheimer’s disease (REFLECT-2)”

2. GlaxoSmithKline: AVA 102675

“A 52-week open-label extension study of long-term safety and efficacy of rosiglitazone extended-release (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild-to-moderate Alzheimer’s disease (REFLECT-4)”.

3. Merck Sharpe & Dohme:

“A Double-Blind, Placebo Controlled, Parallel Group Study to Compare the Efficacy of Rizatriptan 10 mg lyophilized wafer in the Acute Treatment of Migraine in Patients with Unilateral Trigeminal Autonomic Symptoms”.

4. GSK NOS 103325

“A multi-center, two part, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability and pharmacokinetics of the iNOS inhibitor GW274150 administrated up to 120 mg daily for 12 weeks in the prophylactic treatment of migraine”.

5. Teva MS-LAQ-302

“A multinational, multicenter, randomized, parallel-group study performed in subjects with relapsing-remitting multiple sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and of a reference arm of interferon B-1a (Avonex) in a rater-blinded design”.

6. Glaxo-Smithkline AZ3110866

“A fixed dose study of SB742457 versus placebo when added to existing donepezil treatment in subjects with mild-to-moderate Alzheimer’s disease.”

7. Glaxo-Smithkline A4M105038

“A randomized, double-blind, placebo controlled, parallel-group, dose-ranging study to investigate the MRI efficacy and safety of six months administration of finategrast (150-1200 mg twice daily<sup>9</sup> in subjects with relapsing-remitting multiple sclerosis.”

8. Merck Sharpe & Dohme: MK0974 012-00

“A multicentre, double-blind, active-controlled, parallel group study to examine the safety, tolerability and efficacy of oral MK-0974 for the long-term treatment of acute migraine with or without aura”.

9. Merck Sharpe & Dohme. MK-0974-031

“A multicenter, double blind, placebo-controlled, parallel group multiple attacks study to compare the efficacy and safety of oral MK-0974 with placebo for the acute treatment of migraine with or without aura”.

10. Merck Sharpe & Dohme: MK0023-005

“A fase II b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of MK-3207 in the Treatment of Acute Migraine”.

11. Boehringer Ingelheim BI 1246.4

“A multinational, multicenter, randomized, parallel-group study comparing placebo vs BI 44370 ta (50 mg, 200 mg, 400 mg) administered orally during a migraine attack of moderate-severe intensity”.

12. Carisepy 3013/3014

“A Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects with Partial Onset Seizures”.

13. GlaxoSmithKline: ROR104836

“A randomized, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe Restless Legs Syndrome”.

14. Merck Sharpe & Dohme MK0974 011-00

“A multicentre, double-blind, placebo and active-controlled, parallel group study to compare the efficacy and safety of oral MK-0974 with placebo and zolmitriptan for the acute treatment of migraine with or without aura”.

15. Carisepy 3007

“A Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects with Partial Onset Seizures”.

16. Protocol MK 0462-082

“A Worldwide, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Trail to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents”.

17. Merck Sharpe & Dohme: MK0362-085

“A Multicenter, randomized, double-blind, placebo-controlled crossover trial to evaluate the efficacy and tolerability of rizatriptan 10 mg ODT for the treatment of acute migraine in patients on topiramate for migraine prophylaxis”.

18. Istituto Lusofarmaco d'Italia S.p.A.: Lumi/09/Fro+Dex-Mig/001

“Comparison between frovatriptan plus different treatment regimens of dexketoprofen (25 mg and 37.5 mg) and frovatriptan alone in the acute treatment of migraine without aura and migraine with aura attacks”.

19. Glaxo-Smithkline RGB113905

“An open label, Flexible-Dose Study of retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults with Partial Onset Seizures”.

20. Protocol 110390 (ZOSTER-006)

“A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals' gE/AS01B vaccine when administered intramuscularly on a 0, 2-month schedule in adults aged 50 years and older”.

21. Protocol 113077 (ZOSTER-022)

“A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety and immunogenicity of GSK Biologicals' gE/AS01B vaccine when administered intramuscularly on a 0, 2-month schedule in adults aged 70 years and older”.

21. Pfizer Italia A0081186

“A Randomized, double-blind, 12-month study of pregabalin in subjects with restless legs syndrome”.

**22. Glaxo-Smithkline RTG113413**

“An open label, Flexible-Dose Study of retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults with Partial Onset Seizures (extension study RGB113905)”.

**23. LAQ-MS-305 (CONCERTO)**

“A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6 mg/day or 1.2 mg/day) in subjects with relapsing remitting multiple sclerosis (RRMS)”.

**23. Janssen Cilag: GALALZ3005**

“A randomized, double-blind, placebo-controlled trial of long-term (2 year) treatment of galantamine in mild to moderately severe Alzheimer’s disease (GAL-ALZ-3005/PXL 87129)”.

**24. I5Q-MC-CGAI**

“A phase 3 randomized double blind, placebo-controlled study of LY2951742 in patients with chronic migraine – the REGAIN study”.

**25. GSK 204486 Zoster 056 ext 006-022**

“A Phase IIIb, non-randomized, open-label, multi-country, multi-centre, cross-vaccination study to evaluate the safety of GSK biologicals’ herpes zoster subunit (HZ/su) vaccine when administered intramuscularly on a 2-dose scheduled to subjects who previously received placebo in Zoster-006 and Zoster-022 studies”.

**26. GSK 201190 Zoster 049 ext 006-022**

“A Phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogenicity persistence of GSK Biologicals’ Herpes Zoster subunit (HZ/SU) vaccine and assessment of 1 or 2 additional doses on a 0 or 0.2-month schedule in 2 subgroups of older adults”.

**27. TV48125-CNS-30056**

“A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the Prevention of Episodic Cluster Headache”.

**28. TV48125-CNS-30057**

“A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the Prevention of Chronic Cluster Headache”.

**29. TV48125-CNS-30058**

“A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety of TEV-48125 for the Prevention of Cluster Headache”.

**30. ALD 403-CLIN-011**

“A Parallel Group, Double-Blind, Randomized, Placebo-Controlled, Phase III trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Chronic Migraine”.

**31. The BECOME study:**

“The Burden of migraine in specialist headache Centers treating patients with prophylactic treatment failure (The BECOME study)”.

32. Novartis CAMG334A240 (APPRAISE)

“A 12-month prospective, randomized, interventional, global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs. oral prophylactics) in adult episodic migraine patients”.

33. Allergan 3101-303-002

“A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of atogepant for the prevention of chronic migraine (PROGRESS study)”.

34. Amgen 20170703:

“A Phase 4, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Chronic Migraine and Medication Overuse Headache”.

35. Teva TV48125-CNS-30082:

“A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age”.

36. Teva TV48125-CNS-30083:

“A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age”.

37. Teva TV48125-CNS-30084:

“A Multicenter, Open-Label Study Evaluating the Long-Term Safety and Tolerability of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age”.

38. Teva TV48125-MH-40142 (UNITE)

“A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients with Major Depressive Disorder”.

39. Lundbeck 18898A (DELIVERY)

“Interventional, randomized, double-blind, parallel-group, placebo-controlled study with an extension period to evaluate the efficacy and safety of eptinezumab for the prevention of migraine in patients with unsuccessful prior preventive treatments”.

40. Amgen 20191008

“Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase 4 Study”.

41. Novartis CAMG334AIT04 (NEW ERA)

“Italian national study on quality of life and healthcare impact in a real world Erenumab treated migraine population (NEW ERA Study)”.

42. Lundbeck 19386A (ALLEVIATE)

“Interventional, randomized, double-blind, parallel-group, placebo controlled delayed-start study to evaluate the efficacy and safety of eptinezumab in patients with episodic Cluster Headache”.

**43. TV48125-MH-40146**

“PEARL study: a pan-European prospective observational study of fremanezumab effectiveness in patients with chronic or episodic migraine in the real world”.

**44. I5Q-MC-B004 (TRIUMPH)**

“Preventive Treatment of Migraine: Outcomes for Patients in Real-World Healthcare Systems”.

**45. LUN9385A-19385A (CHRONICLE)**

“Interventional, open-label, fixed-dose multiple administrations study to evaluate long-term treatment with eptinezumab in patients with chronic cluster headache”.

**46. EMIKETO**

“A prospective, single blind, parallel group study comparing the effects of low-calorie diet vs very low-calorie ketogenic diet in the prevention of high frequency episodic migraine”

**47. I-GRAINE (Italian miGRAINe rEgistry)**

“A five-year, multicenter, prospective study to assess the socio-demographic, epidemiological, clinical aspects of migraine and its impact on healthcare resource use”.

**48. Eli Lilly 2019-9047 (REALITY):**

“Galcanezumab for the prevention of episodic or chronic migraine in patients treated at Italian headache centres: a real-world, retrospective cohort study”.

**49. BHV-3000-315: Biohaven Pharmaceutical clinical research study:**

“A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents  $\geq 6$  to  $<18$  years of age”.

**50. BHV3000-404: “A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention with Multiple, Dosing Regimens”.**

**60. BHV3000-406: “A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use”.**

**61. BHV3000-407: “A Phase 4, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults with a History of Inadequate Response to Oral Preventive Medications”.**

**62. Chordate System S220: “An open Post-marketing Clinical Follow-up investigation to follow long-term performance and safety of intranasal kinetic oscillation in subjects with Chronic migraine”.**

**63. Organon ICOMM: “The Impact of COVID-19 on the Management of Migraine (ICOMM)”.**

**64. NOE-TGN-201: “A phase II/III Efficacy and Safety Study of Basimglurant in Patients With Trigeminal Neuralgia”.**

**65. IPSEN: “A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults (C-BEOND)”.**

**66. Lundbeck Resolution-2007°: “A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache”.**

**67. Abbvie M22-06: “Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine (TEMPLE)”.**

Il sottoscritto dichiara inoltre che le fotocopie eventualmente allegate sono conformi agli originali in suo possesso e che quanto dichiarato nella domanda e nel presente curriculum corrisponde al vero.

Si allega fotocopia fronte retro di un valido documento di identità.

Roma, 15 Maggio 2025

Dott.ssa Gabriella Egeo

A handwritten signature in black ink, appearing to read 'Gabriella Egeo', with a stylized flourish at the end.